We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Osteotech Initiates Pivotal Clinical Trial for DuraTech™ BioRegeneration Matrix
News

Osteotech Initiates Pivotal Clinical Trial for DuraTech™ BioRegeneration Matrix

Osteotech Initiates Pivotal Clinical Trial for DuraTech™ BioRegeneration Matrix
News

Osteotech Initiates Pivotal Clinical Trial for DuraTech™ BioRegeneration Matrix

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Osteotech Initiates Pivotal Clinical Trial for DuraTech™ BioRegeneration Matrix"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Osteotech, Inc. has announced that it has initiated a pivotal clinical trial for its DuraTech™ BioRegeneration Matrix. The first five patients in this 60-patient trial have already been enrolled.

During the study's initial cranial surgical procedures, the patients' dura mater was successfully repaired by surgeons using the DuraTech BioRegeneration Matrix.

This pivotal clinical trial will evaluate 60 surgical patients at 30 and 90 days post-operatively to assess the safety and efficacy of the DuraTech BioRegeneration Matrix compared to historical surgical procedure outcomes.

Once this trial is completed, Osteotech plans to file a medical device premarket submission, or 510(k), with the United States Food and Drug Administration (FDA). Osteotech anticipates filing the 510(k) during the third quarter of 2009 to secure marketing clearance.

"DuraTech is the first of several extremely promising products that we have in development based on our innovative human collagen technology platform," stated Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer. "Our human collagen platform positions Osteotech as first-in-class with this new biomaterial and enables us to respond to the growing surgeon demand, and address patient need, for safe and clinically effective regenerative healing surgical products."

"DuraTech is designed to stimulate the body's natural bioregenerative processes that accelerate healing and reduce the potential for immune reactions," added Mohammed Attawia, M.D., Osteotech's Vice President of Product Development. "Additionally, surgeon feedback during these preclinical trials indicate that DuraTech is easier to handle and provides greater flexibility during surgery than competitive products."

The DuraTech BioRegeneration Matrix is based on Osteotech's proprietary human collagen technology.

DuraTech will also provide surgeons with the clinical flexibility to cut, shape and suture the material to fit each patient's needs. Based on available data, Osteotech estimates that the market for dural repair substitutes is approximately $100 million.
Advertisement